IGC Pharma, Inc.
About IGC Pharma, Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.3M
- Net income
- -$7.1M
- Total assets
- $8.7M
- Market cap
- $28.6M
- Gross margin
- 48.7%
- Operating margin
- -585.8%
- Net margin
- -560.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.3M
- Cost of revenue
- $652.0K
- Gross profit
- $619.0K
- Operating expenses
- $8.1M
- Operating income
- -$7.4M
- Income tax
- $0
- Net income
- -$7.1M
- EPS (basic)
- $-0.09
- EPS (diluted)
- $-0.09
Balance sheet
- Total assets
- $8.7M
- Current assets
- $2.9M
- Total liabilities
- $2.4M
- Current liabilities
- $2.3M
- Shareholders’ equity
- $6.3M
Cash flow
- Operating cash flow
- -$4.8M
- Investing cash flow
- -$442.0K
- Financing cash flow
- $4.5M
- Net cash flow
- -$786.0K
Statements via Polygon.io (SEC filings)
- Market cap
- $28.6M
- EPS (diluted)
- $-0.09
- Shares outstanding
- 95.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 13, 2006
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $7.1M in FY2025.
- Revenue grew 42% from FY2021 to FY2025.
- Gross margin of 48.7%, net margin -560.3%.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IGC Pharma, Inc..
Write a review
News about IGC Pharma, Inc.
News & sentiment via Polygon.io
